Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
8.0
来源：
Nature
关键字：
CRISPR
发布时间：
2025-09-10 03:43
摘要：
The 2025 EBMT practice recommendations detail the indications for hematopoietic cell transplantation (HCT) and CAR-T therapies for hematological diseases, solid tumors, and immune disorders. The report emphasizes the integration of innovative cellular and gene therapies into clinical practice, reflecting evolving treatment paradigms. It aims to provide guidance based on clinical trials and registry data, advocating for harmonization of practices across EBMT countries to enhance patient outcomes.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
The report provides guidance on HCT indications according to prevailing clinical practice.
Innovative cellular and gene therapies have entered activity across indications affecting clinical decision making.
The recommendations are based on clinical trials, registry data, and expert opinions.
真实性检查
否
AI评分总结
The 2025 EBMT practice recommendations detail the indications for hematopoietic cell transplantation (HCT) and CAR-T therapies for hematological diseases, solid tumors, and immune disorders. The report emphasizes the integration of innovative cellular and gene therapies into clinical practice, reflecting evolving treatment paradigms. It aims to provide guidance based on clinical trials and registry data, advocating for harmonization of practices across EBMT countries to enhance patient outcomes.